Compare BMR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | BCDA |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 15.7M |
| IPO Year | 2021 | 2009 |
| Metric | BMR | BCDA |
|---|---|---|
| Price | $1.09 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 74.7K | ★ 116.9K |
| Earning Date | 08-11-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $479,000.00 |
| Revenue This Year | $0.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.06 | $0.75 |
| 52 Week High | $2.51 | $1.80 |
| Indicator | BMR | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 44.40 |
| Support Level | N/A | $0.82 |
| Resistance Level | $1.40 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 1.44 | 28.14 |
Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).